EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Severity‐Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19‐Targeted CAR T‐Cell Therapy

Andreu Vilaseca iD, Helena Ariño, Gloria Iacoboni, Samantha Feijóo, Ana Zabalza iD, Nicolás Fissolo, María Jesús Arévalo, Cecilia Carpio, Mario Sánchez, Mar Tintoré, Manuel Comabella iD, Xavier Montalban und 2 weitere

European Journal of Neurology · 2025-08 · 32 (8)

DOI: 10.1111/ene.70305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 05.08.2025. Verfasst von Andreu Vilaseca und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and MS Centre of Catalonia (Cemcat), Vall D'hebron University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Neurofilament Proteins, Neurotoxicity Syndromes, Lymphoma, Non-Hodgkin, Antigens, CD19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Immune effector cell‐associated neurotoxicity syndrome (ICANS) is a potential complication following Chimeric Antigen Receptor (CAR) T‐cell infusion. Biomarkers to aid in early diagnosis and severity assessment are lacking. We aim to describe and compare serum neurofilament light chain (sNfL) dynamics in non‐Hodgkin lymphoma (NHL) patients undergoing anti‐CD19 CAR T‐cell therapy, based on ICANS presence and severity.

Methods

This is a case–control study nested within a cohort of NHL patients treated with anti‐CD19 CAR T‐cells at a tertiary care center. From this cohort, we selected those who developed ICANS and had available blood samples. These patients were compared to matched NHL patients without ICANS from the same cohort. sNfL concentrations were measured immediately pre‐infusion and on days 7 and 14 post‐infusion, with z ‐scores calculated against a normative database. Mixed linear and ROC analysis assessed sNfL dynamics by ICANS presence and severity.

Results

Of 159 patients treated, 54 (34%) developed ICANS. We included 32 patients with ICANS and 22 matched controls. Baseline sNfL concentrations were similarly elevated in both ICANS and non‐ICANS patients. However, on day 7, patients with moderate–severe ICANS (grade ≥ 2) had higher sNfL levels (median z ‐score 2.33) than those with mild or no ICANS (median z ‐score 1.72; p = 0.022). The optimal cutoff to discriminate moderate–severe ICANS from other patients based on sNfL was a z ‐score of 2.14 on day 7 ( p = 0.004).

Discussion

Moderate–severe ICANS is associated with elevated sNfL levels by day 7 post‐infusion, indicating early neuroaxonal damage and underscoring sNfL as a valuable biomarker for assessing ICANS severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofilament ProteinsNeurotoxicity SyndromesLymphoma, Non-HodgkinAntigens, CD19Immunotherapy, AdoptiveHumansMaleFemaleMiddle AgedCase-Control StudiesAgedBiomarkersAdultSeverity of Illness Index

Stichwörter der Autor:innen

CAR‐T cellsICANSautoimmune neurologybiomarkerimmunotherapylymphomaneuroaxonal damageoncology

Substanzen

Neurofilament Proteinsneurofilament protein LAntigens, CD19Biomarkers

Autor:innen und Institutionen

  • Department of Neurology and MS Centre of Catalonia (Cemcat), Vall D'hebron University Hospital, Barcelona, Spain.
  • Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Hematology Department, Vall D'hebron University Hospital, Barcelona, Spain.
  • Universitat de Vic-Universitat Central de Catatlunya (UVic-UCC), Vic, Spain.

ORCID-Profile: Andreu Vilaseca, Ana Zabalza, Manuel Comabella, Ángela Vidal-Jordana

Zitieren

APA

Vilaseca, A., Ariño, H., Iacoboni, G., Feijóo, S., Zabalza, A., Fissolo, N., Arévalo, M. J., Carpio, C., Sánchez, M., Tintoré, M., Comabella, M., Montalban, X., Barba, P., & Vidal-Jordana, Á. (2025). Severity‐Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19‐Targeted CAR T‐Cell Therapy. European Journal of Neurology, 32(8). https://doi.org/10.1111/ene.70305

Vancouver

Vilaseca A, Ariño H, Iacoboni G, Feijóo S, Zabalza A, Fissolo N, et al. Severity‐Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19‐Targeted CAR T‐Cell Therapy. European Journal of Neurology. 2025;32(8). doi:10.1111/ene.70305

BibTeX
@article{Vilaseca2025,
  author = {Vilaseca, Andreu and Ariño, Helena and Iacoboni, Gloria and Feijóo, Samantha and Zabalza, Ana and Fissolo, Nicolás and Arévalo, María Jesús and Carpio, Cecilia and Sánchez, Mario and Tintoré, Mar and Comabella, Manuel and Montalban, Xavier and Barba, Pere and Vidal-Jordana, Ángela},
  title = {Severity‐Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19‐Targeted CAR T‐Cell Therapy},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {8},
  doi = {10.1111/ene.70305}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche